Investor Relations

Company Overview

We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, two of our programs are focused on kidney disease that we believe have the potential to offer medical benefit. As we grow the Company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our current development programs are focused on the development of two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Stock Inforamtion

IR Contacts

Company

Unicycive Therapeutics, Inc.
5150 El Camino Real
Suite A-32
Los Altos, CA 94022
T: 650-351-4495
info@unicycive.com

Investor Relations

T: 650-900-5470
ir@unicycive.com

Transfer Agent

Philadelphia Stock Transfer, Inc.
2320 Haverford Road
Ardmore, PA 19003

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.